slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 20,821-20,850
Pages 885
Rows per page 30
Arc
20,821-20,850 of 26,550
23
Data presented as Kaplan-Meier survival curves and tumor growth kinetics/bar charts.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
24
The diagram depicts a biological process flow involving iNKT cells, DCs, MDSCs, and inflammatory monocytes.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
25
The table uses checkmarks, crosses, and question marks to indicate performance/capability across different cell types.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
26
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
27
The slide presents clinical efficacy metrics (ORR, SD, mOS) and safety profile for iNKT cell therapy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
28
The data shows a clear trend where the combination of iNKT activator + Fc enhanced CTLA-4 + PD-1 (Group F) results in the lowest number of metastases.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
29
The slide uses a process flow diagram to show trial progression and a list-based structure for clinical endpoints.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
30
The table displays patient characteristics (age, sex) and disposition (early discontinuation, death, progression) for three distinct dosing groups and the total population.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
31
The chart displays patient outcomes over time, with dots indicating progression and bars indicating stable disease.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
32
Includes a table of adverse events, box plots for cytokines (IL-1b, IL-6, CRP), and a longitudinal line chart for IFNy.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
33
The slide uses a staircase diagram to represent dose escalation levels.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
34
The slide presents a patient cohort table and a specific case study (Patient 6) showing M-spike protein and plasma cell levels over time.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
35
The slide presents clinical trial safety data including a table of adverse events and dot plots for inflammatory markers.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · EvidenceLoop · Before After1 hit
36
Includes references to SITC #372 and NCT05108623.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
37
Includes abstract number 372.Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
38
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
39
The slide uses a three-column layout to present distinct biological mechanisms supported by experimental data (line and bar charts).Mink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
40
Mink Therapeutics | Investor Day Presentation Deck | 92 slidesMink Therapeutics | Investor Day Presentation Deck | 92 slides · MiNK Therapeutics
Conference presentation Investor relations Beat · Key Takeaways1 hit
01
Taboola | Mergers and Acquisitions Presentation Deck | 13 slidesTaboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Setup1 hit
02
Taboola | Mergers and Acquisitions Presentation Deck | 13 slidesTaboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Setup1 hit
03
Confetti background suggests a celebratory tone.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Setup1 hit
04
The slide features a purple background with the logos of Yahoo and Taboola, and an inverted image of a person laughing.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Setup1 hit
05
The slide uses screenshots of Yahoo's mobile interface with purple boxes highlighting the ad placements.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Complication1 hit
06
The slide outlines the value proposition of a specific business partnership.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Complication1 hit
07
Uses a before-after comparison to illustrate the scale of the acquisition.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Problem (Identify pain)Loop · Before After1 hit
08
The table highlights accretion in both Revenue/Share and Adjusted EBITDA/Share.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Problem (Identify pain)Loop · Before After1 hit
09
Taboola | Mergers and Acquisitions Presentation Deck | 13 slidesTaboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
10
Taboola | Mergers and Acquisitions Presentation Deck | 13 slidesTaboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Solution (Provide relief)Loop · Cost Of Inaction1 hit
11
Taboola | Mergers and Acquisitions Presentation Deck | 13 slidesTaboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Resolution1 hit
12
The slide serves as a disclosure of the underlying logic for a hypothetical financial scenario.Taboola | Mergers and Acquisitions Presentation Deck | 13 slides · Taboola
Shareholder letter Investment bank Beat · Resolution1 hit